Shuttle Pharmaceuticals Holdings has the GF Score of 24, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Shuttle Pharmaceuticals Holdings
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Shuttle Pharmaceuticals Holdings GF Score Related Terms
SHPH vs UPC, CBIH, CPMD: GF Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shuttle Pharmaceuticals Holdings's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shuttle Pharmaceuticals Holdings GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shuttle Pharmaceuticals Holdings's GF Score distribution charts can be found below:
* The bar in red indicates where Shuttle Pharmaceuticals Holdings's GF Score falls into.
Shuttle Pharmaceuticals Holdings (SHPH) has a GF Score of 24 as of Jun. 29, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Shuttle Pharmaceuticals Holdings and its competitors. This is 14% above median its historical median of 21.00. Over the past decade, Shuttle Pharmaceuticals Holdings' GF Score has ranged from 12.00 to 39.00.
Is Shuttle Pharmaceuticals Holdings' GF Score too high?
Shuttle Pharmaceuticals Holdings' current GF Score of 24 is 14% above median its 10-year median of 21.00. Over the past 10 years, this metric has ranged from a low of 12.00 to a high of 39.00. Overall, Shuttle Pharmaceuticals Holdings has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Shuttle Pharmaceuticals Holdings' GF Score compare to UPC and CBIH?
Shuttle Pharmaceuticals Holdings' GF Score of 24 can be compared against companies in the Drug Manufacturers industry. Historically, Shuttle Pharmaceuticals Holdings' own GF Score has ranged from 12.00 to 39.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Shuttle Pharmaceuticals Holdings and its competitors. Shuttle Pharmaceuticals Holdings's current GF Score is 24, which is 14% above median its own 10-year median of 21.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shuttle Pharmaceuticals Holdings stock overvalued right now?
Shuttle Pharmaceuticals Holdings (SHPH) has a current GF Score of 24. The current GF Score is 24, which is 14% above median its 10-year median of 21.00. Shuttle Pharmaceuticals Holdings' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Shuttle Pharmaceuticals Holdings (SHPH), the current GF Score is 24 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shuttle Pharmaceuticals Holdings Business Description
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
24GF Score
Get the complete analysis for SHPH
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPH has been successfully added to your 